Following the footsteps of AstraZeneca, Pfizer-BioNtech has 94% effectiveness after two jabs, per Reuters. As per the news, "The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing COVID-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies."
However, Bloomberg cites 22.7% American having no plans to get vaccinated. "Low levels of vaccinations in some regions could pose a problem for local authorities trying to reopen schools and businesses seeking to get staff back into the workplace, as well as more cases of the disease," said the news.
Risks got another boost...
Although the US citizens aren't sure about getting immuned, markets cheered the vaccine news amid the persistent risk-on mood. This follows Wall Street's strong closing on Wednesday and a jump in the US 10-year Treasury yeilds. As a result, S&P 500 Futures can start Thursday on a firm note, which in turn should offer extra strength to the commodities and Antipodeans.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.